Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside report.

Literature DB >> 26917690

Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside report.

Vivek Subbiah¹, David S Hong², Funda Meric-Bernstam².

Abstract

Entities: Chemical Disease Gene

Mesh：

Substances：

Year: 2016 PMID： 26917690 PMCID： PMC4801313 DOI： 10.1073/pnas.1522052113

Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN： 0027-8424 Impact factor: 11.205

× No keyword cloud information.

5 in total

1. Crizotinib in ROS1-rearranged non-small-cell lung cancer.

Authors: Alice T Shaw; Sai-Hong I Ou; Yung-Jue Bang; D Ross Camidge; Benjamin J Solomon; Ravi Salgia; Gregory J Riely; Marileila Varella-Garcia; Geoffrey I Shapiro; Daniel B Costa; Robert C Doebele; Long Phi Le; Zongli Zheng; Weiwei Tan; Patricia Stephenson; S Martin Shreeve; Lesley M Tye; James G Christensen; Keith D Wilner; Jeffrey W Clark; A John Iafrate
Journal: N Engl J Med Date: 2014-09-27 Impact factor: 91.245

2. Ceritinib in ALK-rearranged non-small-cell lung cancer.

Authors: Liang Shen; Hong-Fang Ji
Journal: N Engl J Med Date: 2014-06-26 Impact factor: 91.245

3. Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.

Authors: Monika A Davare; Nadeem A Vellore; Jacob P Wagner; Christopher A Eide; James R Goodman; Alexander Drilon; Michael W Deininger; Thomas O'Hare; Brian J Druker
Journal: Proc Natl Acad Sci U S A Date: 2015-09-08 Impact factor: 11.205

4. Ceritinib in ALK-rearranged non-small-cell lung cancer.

Authors: Alice T Shaw; Dong-Wan Kim; Ranee Mehra; Daniel S W Tan; Enriqueta Felip; Laura Q M Chow; D Ross Camidge; Johan Vansteenkiste; Sunil Sharma; Tommaso De Pas; Gregory J Riely; Benjamin J Solomon; Juergen Wolf; Michael Thomas; Martin Schuler; Geoffrey Liu; Armando Santoro; Yvonne Y Lau; Meredith Goldwasser; Anthony L Boral; Jeffrey A Engelman
Journal: N Engl J Med Date: 2014-03-27 Impact factor: 91.245

5. The Signature Program: Bringing the Protocol to the Patient.

Authors: B P Kang; E Slosberg; S Snodgrass; C Lebedinsky; D A Berry; C L Corless; S Stein; A Salvado
Journal: Clin Pharmacol Ther Date: 2015-05-11 Impact factor: 6.875

5 in total

11 in total

1. Debunking the Delusion That Precision Oncology Is an Illusion.

Authors: Vivek Subbiah; Razelle Kurzrock
Journal: Oncologist Date: 2017-05-26

Review 2. Latest perspectives of orally bioavailable 2,4-diarylaminopyrimidine analogues (DAAPalogues) as anaplastic lymphoma kinase inhibitors: discovery and clinical developments.

Authors: Muhammad Latif; Zaman Ashraf; Sulman Basit; Abdul Ghaffar; Muhammad Sohail Zafar; Aamer Saeed; Sultan Ayoub Meo
Journal: RSC Adv Date: 2018-05-04 Impact factor: 4.036

Review 3. Prioritizing molecular markers to test for in the initial workup of advanced non-small cell lung cancer: wants versus needs.

Authors: Howard West
Journal: Ann Transl Med Date: 2017-09

4. Emerging resistance pathways in lung cancer: what has ROS-1 taught us?

Authors: Doraid Alrifai; Martin D Forster; Sam M Janes
Journal: Transl Lung Cancer Res Date: 2018-02

Review 5. Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy.

Authors: Mariacarmela Santarpia; Maria Grazia Daffinà; Alessandro D'Aveni; Grazia Marabello; Alessia Liguori; Elisa Giovannetti; Niki Karachaliou; Maria Gonzalez Cao; Rafael Rosell; Giuseppe Altavilla
Journal: Drug Des Devel Ther Date: 2017-07-05 Impact factor: 4.162

10. Oncogenic driver mutations, treatment, and EGFR-TKI resistance in a Caucasian population with non-small cell lung cancer: survival in clinical practice.

Authors: Albrecht Stenzinger; Jörn Sträter; Martin Faehling; Birgit Schwenk; Sebastian Kramberg; Robert Eckert; Anna-Lena Volckmar
Journal: Oncotarget Date: 2017-09-13